What is the current valuation of the India Sickle Cell Disease Market?

The market valuation was 0.259 USD Billion in 2024. Read More

What is the projected market size for the India Sickle Cell Disease Market by 2035?

The projected valuation for 2035 is 0.92 USD Billion. Read More

What is the expected CAGR for the India Sickle Cell Disease Market during the forecast period?

The expected CAGR from 2025 to 2035 is 12.22%. Read More

Which companies are the key players in the India Sickle Cell Disease Market?

Key players include Bristol Myers Squibb, Novartis, Pfizer, Roche, Amgen, Boehringer Ingelheim, Sanofi, Celgene, and GSK. Read More

What are the main applications in the India Sickle Cell Disease Market?

Main applications include Blood Transfusion, Gene Therapy, Hydroxyurea Therapy, Pain Management, and Vaccination. Read More

How does the market segment by treatment type for Sickle Cell Disease?

The market segments by treatment type include Curative Treatment, Preventive Treatment, Symptomatic Treatment, and Supportive Treatment. Read More

What demographic segments are considered in the India Sickle Cell Disease Market?

Demographic segments include Pediatric Patients, Adult Patients, Geriatric Patients, and Pregnant Women. Read More

What diagnosis methods are utilized in the India Sickle Cell Disease Market?

Diagnosis methods include Blood Tests, Genetic Testing, Newborn Screening, and Clinical Evaluation. Read More

What was the market valuation for Blood Transfusion in 2024?

The market valuation for Blood Transfusion was 0.065 USD Billion in 2024. Read More

What is the projected market size for Hydroxyurea Therapy by 2035?

The projected market size for Hydroxyurea Therapy is expected to reach 0.3 USD Billion by 2035. Read More

India Sickle Cell Anaemia Market

ID: MRFR/LS/20445-CR

76 Pages

Nidhi Mandole

Last Updated: April 02, 2026

India Sickle Cell Anaemia Market Research Report Information by Type (Sickle Cell Anemia (SS), Sickle Hemoglobin-C Disease (SC), Sickle Beta-Plus Thalassemia, and Sickle Beta-Zero Thalassemia) by Diagnosis & Treatment Type [(Diagnosis (Instruments and Reagents and kits), Treatment, (Pharmacotherapy, (Oral and Parenteral), Blood Transfusion, and Bone Marrow Transplant)] - Forecast till 2035

India Sickle Cell Anaemia Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Blood Transfusion
  2. 4.1.2 Gene Therapy
  3. 4.1.3 Hydroxyurea Therapy
  4. 4.1.4 Pain Management
  5. 4.1.5 Vaccination
2. 4.2 Healthcare, BY Treatment Type (USD Billion)
  1. 4.2.1 Curative Treatment
  2. 4.2.2 Preventive Treatment
  3. 4.2.3 Symptomatic Treatment
  4. 4.2.4 Supportive Treatment
3. 4.3 Healthcare, BY Patient Demographics (USD Billion)
  1. 4.3.1 Pediatric Patients
  2. 4.3.2 Adult Patients
  3. 4.3.3 Geriatric Patients
  4. 4.3.4 Pregnant Women
4. 4.4 Healthcare, BY Diagnosis Method (USD Billion)
  1. 4.4.1 Blood Tests
  2. 4.4.2 Genetic Testing
  3. 4.4.3 Newborn Screening
  4. 4.4.4 Clinical Evaluation
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Bristol Myers Squibb (IN)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (IN)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer (IN)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Roche (IN)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Amgen (IN)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Boehringer Ingelheim (IN)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (IN)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Celgene (IN)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 GSK (IN)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 INDIA MARKET ANALYSIS BY APPLICATION
3. 6.3 INDIA MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
5. 6.5 INDIA MARKET ANALYSIS BY DIAGNOSIS METHOD
6. 6.6 KEY BUYING CRITERIA OF HEALTHCARE
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF HEALTHCARE
9. 6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
10. 6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
12. 6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
14. 6.14 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
15. 6.15 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Billion)
16. 6.16 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
17. 6.17 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
18. 6.18 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
19. 6.19 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY TREATMENT TYPE, 2026-2035 (USD Billion)
  3. 7.2.3 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
  4. 7.2.4 BY DIAGNOSIS METHOD, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

India Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

Blood Transfusion
Gene Therapy
Hydroxyurea Therapy
Pain Management
Vaccination

Healthcare By Treatment Type (USD Billion, 2026-2035)

Curative Treatment
Preventive Treatment
Symptomatic Treatment
Supportive Treatment

Healthcare By Patient Demographics (USD Billion, 2026-2035)

Pediatric Patients
Adult Patients
Geriatric Patients
Pregnant Women

Healthcare By Diagnosis Method (USD Billion, 2026-2035)

Blood Tests
Genetic Testing
Newborn Screening
Clinical Evaluation

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”